Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Angion Biomedica (ANGN) stocks in Canada

Learn how to easily invest in Angion Biomedica stocks.

Angion Biomedica is a biotechnology business based in the US. Angion Biomedica stocks (ANGN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $11.15 – an increase of 11.82% over the previous week. Angion Biomedica employs 71 staff and has a trailing 12-month revenue of around $29.6 million.

How to buy stocks in Angion Biomedica

  1. Compare stock trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – ANGN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of stocks with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Angion Biomedica stock price (NASDAQ:ANGN)

Use our graph to track the performance of ANGN stocks over time.

Angion Biomedica shares at a glance

Information last updated 2022-05-21.
Latest market close$1.23
52-week range$1.08 - $16.04
50-day moving average $1.74
200-day moving average $4.67
Wall St. target price$15.00
PE ratio N/A
Dividend yield $0 (0%)
Earnings per share (TTM) $-1.08

Compare stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Young investors 18 to 24 can get free online trades and a $0 annual account fee. Conditions apply.
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get almost $500 in commission free trades when you fund your new account with a minimum of $10,000. Conditions apply. Ends August 31, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy Angion Biomedica stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Angion Biomedica price performance over time

Historical closes compared with the close of $1.23 from 2022-05-24

1 week (2022-05-18) 11.82%
1 month (2022-04-26) -9.56%
3 months (2022-02-25) -40.29%
6 months (2021-11-26) -67.20%
1 year (2021-05-26) -91.74%
2 years (2020-05-22) N/A
3 years (2019-05-22) N/A
5 years (2017-05-22) N/A

Angion Biomedica financials

Revenue TTM $29.6 million
Gross profit TTM $-20,819,000
Return on assets TTM -17.38%
Return on equity TTM -40.25%
Profit margin -108.57%
Book value $2.24
Market capitalisation $38.3 million

TTM: trailing 12 months

Angion Biomedica share dividends

We're not expecting Angion Biomedica to pay a dividend over the next 12 months.

Angion Biomedica overview

Angion Biomedica Corp. , a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapeutics for acute organ injuries and fibrotic diseases. The company's lead product candidate is ANG-3070, an oral tyrosine kinase receptor inhibitor in development as a treatment for fibrotic diseases, primarily in the kidney and lung. It also develops ANG-3777, a hepatocyte growth factor mimetic to treat acute organ injuries, such as delayed graft function; ROCK2 inhibitors programs for fibrotic diseases; and CYP11B2 inhibitor program. The company was incorporated in 1998 and is based in Uniondale, New York. .

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site